Jazz Pharmaceuticals plc – Ordinary Shares (JAZZ) was Upgraded by Sun Trust Rbsn Humphrey to ” Buy”. Earlier the firm had a rating of “Neutral ” on the company shares. Sun Trust Rbsn Humphrey advised their investors in a research report released on Apr 25, 2016.
Many Wall Street Analysts have commented on Jazz Pharmaceuticals plc – Ordinary Shares. Shares were Reiterated by Mizuho on Feb 24, 2016 to “Neutral” and Lowered the Price Target to $ 124 from a previous price target of $140 .Jazz Pharmaceuticals plc – Ordinary Shares was Initiated by Wells Fargo to “Outperform” on Feb 19, 2016.
On the company’s financial health, Jazz Pharmaceuticals plc – Ordinary Shares reported $2.60 EPS for the quarter, based on the information available during the earnings call on Feb 23, 2016. Analyst had a consensus estimate of $2.60. The company had revenue of $340.90 million for the quarter, compared to analysts expectations of $349.83 million. The company’s revenue was up 3.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.44 EPS.
Jazz Pharmaceuticals plc – Ordinary Shares opened for trading at $155.51 and hit $157.43 on the upside on Friday, eventually ending the session at $157.16, with a gain of 0.67% or 1.04 points. The heightened volatility saw the trading volume jump to 6,26,003 shares. Company has a market cap of $9,616 M.
In a different news, on Apr 18, 2016, Michael Patrick Miller (SVP, US Commercial) sold 100 shares at $145.79 per share price. According to the SEC, on Apr 15, 2016, Karen J Wilson (SVP, Finance & PAO) sold 5,007 shares at $150.00 per share price. On Apr 13, 2016, Russell J. Cox (EVP & COO) sold 4,000 shares at $136.98 per share price, according to the Form-4 filing with the securities and exchange commission.